{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-073889","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2022-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.554467+00:00","generated_at":"2026-06-24T23:47:03.653313+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Celldex settles Kolltan merger litigation; replaces up to $172.5M milestones with up to $82.5M in payments","bullets":["Celldex to pay $15M cash upon signing formal settlement agreement; trial set for June 21, 2022 vacated.","Additional $15M due upon successful completion of Phase 2 trial of CDX-0159 (barzolvolimab), net of $2.5M credit.","Additional $52.5M upon first US FDA or EMA regulatory approval of a surviving company product.","New payments replace prior contingent milestones of up to $172.5M under the 2016 Merger Agreement; broad mutual releases.","Celldex maintains guidance; cash expected to fund operations through 2025 after paying the $15M initial payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-073889","json":"https://secwatch.observer/filing/0001104659-22-073889.json","markdown":"https://secwatch.observer/filing/0001104659-22-073889.md","text":"https://secwatch.observer/filing/0001104659-22-073889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000110465922073889/0001104659-22-073889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000110465922073889/tm2219126d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T23:47:03.653313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}